Phthalylsulfathiazole

Summary

Phthalylsulfathiazole (CHEMBL1524273) is an approved small molecule (ATC A07AB02).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A07AB02
• Chemistry: 403.4 Da · C17H13N3O5S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1524273
Name	Phthalylsulfathiazole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4806
ChEBI	CHEBI:9336
ATC	A07AB02
Molecular formula	C17H13N3O5S2
Molecular weight	403.4
InChIKey	PBMSWVPMRUJMPE-UHFFFAOYSA-N

SMILES: C1=CC=C(C(=C1)C(=O)NC2=CC=C(C=C2)S(=O)(=O)NC3=NC=CS3)C(=O)O

IUPAC name: 2-[[4-(1,3-thiazol-2-ylsulfamoyl)phenyl]carbamoyl]benzoic acid

ChEBI definition: A sulfonamide incorporating 2-carboxybenzamido and 1,3-thiazol-2-yl moieties that is a broad-spectrum antibiotic indicated in the treatment of dysentery, colitis, gastroenteritis and intestinal surgery.

Also known as: Ftalilsulfatiazol, NSC-66454, NSC-683525, Phtalylsulfathiazol, Phthalylsulfathiazole, Phthalylsulfhathiazole, Sulfathalidine, Thalazole, SID11112227, SID56463086, SID104171288, PHTHALYLSULFATHIAZOLE

Patent coverage: 596 distinct patent families (2,036 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prostaglandin G/H synthase 1, Cytochrome P450 3A4.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 5 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP3A4	8.9	AC50	1.26	nM	CHEMBL_ACT_6053572
CYP3A4	8.89	Potency	1.3	nM	CHEMBL_ACT_4998037
CYP3A4	8.89	Potency	1.3	nM	CHEMBL_ACT_5066789
PTGS1	5.05	AC50	8948	nM	CHEMBL_ACT_25205785

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).